Ivermectin, a drug best known for treating parasitic infections, has shown unexpected effects on blood sugar, cholesterol, and fat metabolism in laboratory and animal studies. None of these findings have led to approved diabetes treatments, and no large human trials have tested ivermectin specifically as a metabolic therapy. But the preclinical evidence is surprisingly broad, touching several different biological pathways that are central to how the body handles glucose and lipids. Understanding what researchers have found so far, and where the gaps remain, helps explain why this connection keeps attracting scientific attention.
Lowering Blood Sugar Through a Receptor Nobody Expected
The first major discovery linking ivermectin to metabolic regulation came from a high-throughput screening of compound libraries, where researchers identified ivermectin as a ligand for a nuclear receptor called FXR (farnesoid X receptor). FXR is already well established as a regulator of bile acid, cholesterol, and glucose metabolism. When researchers treated normal mice with ivermectin, serum glucose and cholesterol levels dropped. Crucially, the same treatment had no effect in mice that lacked the FXR gene, which strongly suggests ivermectin’s metabolic effects in that model work specifically through this receptor rather than through some unrelated mechanism.1PubMed. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism
FXR is not some obscure research curiosity. It is already a drug target for liver and metabolic diseases. Obeticholic acid, for example, was developed as an FXR agonist for certain liver conditions. Ivermectin appears to activate FXR with distinctive properties in how it recruits coregulator proteins, meaning it does not simply mimic what other FXR-activating compounds do. Whether this difference matters for metabolic outcomes in humans remains unknown, but the finding opened up a line of research that had not been considered before: that an existing, widely used antiparasitic drug might have metabolic “side benefits” baked into its chemistry.
A Direct Effect on Insulin-Producing Cells
Separate from the FXR pathway, researchers studying circadian clock disruption in pancreatic beta cells stumbled onto ivermectin as a compound that could restore insulin secretion. Beta cells are the cells in the pancreas that sense blood glucose and release insulin in response. When circadian clock genes in these cells are disrupted, as happens in certain models of type 2 diabetes, insulin secretion becomes impaired. In a small-molecule screen designed to find compounds that could reverse this failure, ivermectin emerged as one of the hits.2PubMed Central. P2Y1 purinergic receptor identified as a diabetes target in a small-molecule screen to reverse circadian β-cell failure
Single-cell electrophysiology experiments confirmed that ivermectin acts as a glucose-dependent insulin secretagogue, meaning it stimulates insulin release only when glucose is already elevated, not indiscriminately. That is a desirable property in any potential diabetes treatment, because drugs that force insulin release regardless of blood sugar levels carry serious hypoglycemia risk. The researchers traced ivermectin’s insulinotropic action to the P2Y1 purinergic receptor, which they found to be controlled by the circadian clock machinery. In both circadian-disrupted mouse islets and human cadaveric islets, ivermectin promoted insulin secretion through this receptor.2PubMed Central. P2Y1 purinergic receptor identified as a diabetes target in a small-molecule screen to reverse circadian β-cell failure
The circadian angle here is worth pausing on. There is growing recognition that disrupted body clocks contribute to metabolic disease. Shift workers, for instance, have elevated diabetes risk, and clock gene mutations in animal models reliably produce metabolic dysfunction. Finding that ivermectin can partially rescue insulin secretion in clock-disrupted beta cells suggests it might be tapping into a pathway that is specifically relevant to how circadian disruption worsens diabetes, not just general insulin mechanics.
Fat Metabolism in the Liver
Ivermectin’s metabolic footprint extends well beyond glucose. In liver cells loaded with palmitic acid (a saturated fat) to mimic the fatty liver conditions common in people with metabolic syndrome, ivermectin activated AMPK, a key energy-sensing enzyme that essentially tells cells to stop storing fat and start burning it. In one study using HepG2 hepatocytes, ivermectin boosted the phosphorylated (active) form of AMPK by roughly 133% compared to controls. It also suppressed the expression of several genes involved in fat production, including a gene called SREBP1, which dropped by about 11%, and DGAT2, which dropped by about 46%.3PubMed Central. Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte
These are not trivial changes. SREBP1 controls the master switch for making new fat in liver cells, and DGAT2 catalyzes a late step in triglyceride synthesis. ACC, another enzyme in the fat-production chain, also dropped with ivermectin treatment, particularly at higher concentrations. The combined picture is of a drug that, at least in cell culture, dials down the liver’s fat-manufacturing machinery while ramping up the signals that promote energy expenditure.3PubMed Central. Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte
Animal studies support this direction. In rats that had liver damage induced by valproic acid (a drug known to cause fatty liver as a side effect), ivermectin treatment significantly reduced total cholesterol and triglyceride levels. At the higher of two ivermectin doses tested, liver histology showed that large lipid droplets had almost completely disappeared.4Brazilian Journal of Pharmaceutical Sciences. Five-day administration of ivermectin is effective in attenuating valproic acid-induced liver toxicity in rats Fatty liver disease and type 2 diabetes are closely intertwined, so a drug that reduces liver fat accumulation could, in theory, improve insulin sensitivity as a downstream effect. But these are short-duration rodent experiments, and liver cells in a dish are far from a human metabolic system.
Blocking Fat Cell Formation
The lipid story does not stop at the liver. In preadipocyte cells (the precursors that mature into fat-storing adipocytes), ivermectin inhibited differentiation and triglyceride accumulation. The drug’s anti-fat-storage effects were most pronounced when applied during the middle-to-late stage of adipocyte differentiation, suggesting ivermectin interferes with a specific window of the maturation process rather than being broadly toxic to the cells.5PubMed Central. Ivermectin decreases triglyceride accumulation by inhibiting adipogenesis of 3T3-L1 preadipocytes
At the molecular level, ivermectin reduced protein levels of PPARγ and C/EBPα, two transcription factors that are essentially required for a precursor cell to become a mature fat cell. It also reduced ACC, and it altered the expression of genes involved in fatty acid synthesis, uptake, and oxidation. Interestingly, ivermectin enhanced expression of two subunits of the glycine receptor (GlyR), a ligand-gated ion channel. Ivermectin is already known to interact with several ion channels, including glutamate-gated chloride channels in parasites, so this may represent yet another receptor-level mechanism through which it influences metabolic cell behavior.5PubMed Central. Ivermectin decreases triglyceride accumulation by inhibiting adipogenesis of 3T3-L1 preadipocytes
If fewer precursor cells become fat cells, and existing fat production in the liver is suppressed, the net effect could be a reduction in the kind of excess lipid storage that drives insulin resistance. Again, this is cell-culture work, and the concentrations of ivermectin used in these experiments may not reflect what is achievable in a person taking standard antiparasitic doses. But the consistency of findings across different cell types and labs is what keeps the hypothesis alive.
Glucose Transport and Cellular Energy Use
A separate line of research, originally focused on cancer biology rather than diabetes, found that ivermectin affects how cells take up and process glucose. In glioma (brain tumor) cells, ivermectin reduced levels of GLUT4, a glucose transporter protein that is also centrally important in diabetes. It decreased ATP and pyruvate content, reduced the activity of key glycolysis enzymes, and promoted glucose uptake in a pattern consistent with disrupted energy metabolism in the tumor cells.6Wiley Online Library. Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation
The relevance to diabetes here requires some caution. GLUT4 is the insulin-responsive glucose transporter in muscle and fat tissue, and its function is central to how the body clears glucose from the blood after a meal. In cancer cells, suppressing GLUT4 starves the tumor. But in diabetes, you actually want more GLUT4 activity in muscle and fat, not less, because impaired GLUT4 trafficking is one of the hallmarks of insulin resistance. So the cancer-cell finding might seem like bad news for any metabolic-benefit hypothesis.
The resolution may lie in tissue specificity. What ivermectin does to a rapidly dividing glioma cell in a dish is not necessarily what it does to a liver cell, a beta cell, or a muscle fiber in a living organism. The FXR and P2Y1 receptor findings from other studies point toward glucose-lowering and insulin-sensitizing effects in the whole animal, even if individual cell-type experiments sometimes show seemingly contradictory mechanisms. Researchers have not yet sorted out which pathways dominate in vivo. That ambiguity is honest, not a weakness of the research; it simply reflects how early these investigations are.
The Gut Microbiome Angle
Because ivermectin is taken orally in its standard formulation and passes through the gastrointestinal tract, researchers have asked whether it affects the gut microbiome in ways that could indirectly influence metabolism. The gut microbiome is increasingly recognized as a player in metabolic health, with certain bacterial compositions associated with obesity, insulin resistance, and inflammatory states.
Using an in vitro gut model, one study found that ivermectin introduced only minor and temporary changes to the microbial community. Importantly, it did not cause dysbiosis (a significant, harmful disruption of gut bacteria) in conditions meant to represent a healthy adult gut. One notable observation was a predicted and detected increase in short-chain fatty acid production, which is generally considered metabolically beneficial. Short-chain fatty acids like butyrate improve gut barrier integrity and have been linked to better insulin sensitivity.7PubMed Central. Impact of Ivermectin on the Gut Microbial Ecosystem The study also noted that the soluble fiber content in feed appeared to protect gut bacteria from ivermectin’s effects, suggesting that diet context matters.
Not all microbiome findings are benign, however. A comprehensive review of preclinical and clinical data found that in rats treated with avermectin (a close chemical relative of ivermectin) at higher doses for a week, gut bacterial composition shifted more substantially. Alpha diversity increased, the ratio of major bacterial groups changed, and correlation analyses linked these microbial shifts to changes in liver metabolites.8The Microbe. Ivermectin impact over gut microbiota diversity: A comprehensive and updated analysis from pre-clinical and clinical evaluations Whether these microbiome-liver interactions produce net positive or negative metabolic outcomes likely depends on dose, duration, and the individual’s baseline gut health. The evidence so far suggests that standard antiparasitic doses in healthy people are unlikely to cause lasting microbial disruption, but higher or prolonged doses remain a question mark.
Why You Cannot Take Ivermectin for Diabetes
The gap between these laboratory findings and a usable diabetes treatment is vast, and it is worth being explicit about why. First, nearly all the metabolic data comes from cell lines and rodent models. Mice and rats metabolize drugs differently than humans, achieve different tissue concentrations, and have different metabolic physiology. A finding that ivermectin lowers blood sugar in mice fed a particular diet tells you that a biological pathway exists; it does not tell you that the same thing will happen in a person with type 2 diabetes.
Second, dose is a major unresolved question. The concentrations of ivermectin used in cell-culture experiments often far exceed what is achievable in human blood at approved doses. Standard antiparasitic dosing in humans produces peak blood levels that may not be high enough to meaningfully activate FXR, suppress adipogenesis, or stimulate P2Y1 receptor-mediated insulin secretion. Achieving higher levels would raise safety concerns, because ivermectin at supratherapeutic doses can cause neurological side effects.
Third, no randomized controlled trial has tested ivermectin as a treatment for diabetes or metabolic syndrome in humans. There are occasional observational reports from populations receiving mass ivermectin distribution for parasitic diseases, but these lack the controls and design needed to draw conclusions about metabolic effects. Without human efficacy data, the metabolic connection remains a preclinical hypothesis.
What Researchers Are Actually Watching
The most promising thread for future development is probably not ivermectin itself but the targets it has helped identify. The P2Y1 receptor finding, for example, is noteworthy because it suggests a new mechanism for stimulating insulin secretion that is tied to the circadian clock. Even if ivermectin is not the right drug to exploit this pathway in patients (because of dose limitations or off-target effects), knowing that P2Y1 is a clock-controlled diabetes-relevant target could lead to purpose-built drugs that hit the same receptor more selectively.2PubMed Central. P2Y1 purinergic receptor identified as a diabetes target in a small-molecule screen to reverse circadian β-cell failure
Similarly, the FXR connection has value beyond ivermectin. FXR agonists are already in clinical development for nonalcoholic steatohepatitis and related liver diseases, and some of these conditions overlap heavily with the metabolic syndrome that precedes type 2 diabetes. Knowing that ivermectin interacts with FXR in a distinctive way compared to other agonists adds a tool for understanding the receptor’s biology, even if ivermectin never becomes the clinical FXR drug of choice for metabolic disease.1PubMed. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism
The anti-adipogenesis findings may also eventually inform obesity research, where preventing the formation of new fat cells is one strategy being explored alongside reducing the size of existing ones. And the AMPK activation seen in liver cells connects to a pathway that metformin, the most widely prescribed diabetes drug in the world, also engages, though through a different mechanism. The parallels are intriguing, but parallels are not equivalence.
Metabolic Effects People on Ivermectin Might Actually Notice
For the millions of people who take ivermectin periodically for conditions like river blindness or strongyloidiasis, or who received it during the pandemic, a reasonable question is whether they might experience any metabolic changes at standard doses. The honest answer is that any effect is almost certainly too small to notice. Standard antiparasitic courses are brief, usually one to three days, and the blood levels achieved are far lower than those used in the cell and animal experiments described above.
There is no published evidence that people on standard ivermectin courses experience clinically meaningful changes in blood sugar, cholesterol, or body weight. The drug’s metabolic effects appear to require either sustained exposure, higher concentrations, or both. For someone already taking metformin or another diabetes medication, there is no established interaction between ivermectin and standard diabetes drugs at antiparasitic doses, though anyone on complex medication regimens should flag all their prescriptions with their prescriber.
The microbiome data offers a small reassurance here as well: at standard doses, ivermectin’s impact on gut bacteria appears minor and temporary, meaning short courses are unlikely to knock your gut ecosystem off balance in a way that would affect metabolic health. The situation may differ with higher or more prolonged dosing, but that falls outside normal clinical use.
How Ivermectin Compares to Established Metabolic Drug Repurposing
Drug repurposing, where a medication approved for one condition turns out to be useful for another, has a long history in metabolic medicine. Metformin was originally an antimalarial compound. GLP-1 receptor agonists were developed from a peptide found in Gila monster venom. SGLT2 inhibitors trace back to a compound isolated from apple tree bark in the 1800s. The path from “interesting preclinical signal” to “approved metabolic therapy” is neither short nor guaranteed, but it does happen.
Ivermectin’s metabolic story is currently where metformin’s was decades ago: scattered findings across multiple pathways, strong enough to be taken seriously but nowhere near clinical validation. The key difference is that metformin’s glucose-lowering effects were observed in human patients early on, whereas ivermectin’s metabolic signals remain almost entirely in preclinical models. Until someone runs properly designed human studies specifically measuring metabolic endpoints, the connection between ivermectin and diabetes will stay in the “biologically plausible but clinically unproven” category. That is not a dismissal. In pharmacology, biologically plausible hypotheses backed by consistent preclinical data across multiple labs are exactly the kind of leads that sometimes pan out, even if most of them do not.